- Home
- MCS vs ARVN Comparison
MCS vs ARVN Comparison
Compare MCS & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCS
- ARVN
- Stock Information
- Founded
- MCS 1935
- ARVN 2015
- Country
- MCS United States
- ARVN United States
- Employees
- MCS N/A
- ARVN N/A
- Industry
- MCS Movies/Entertainment
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- MCS Consumer Discretionary
- ARVN Health Care
- Exchange
- MCS Nasdaq
- ARVN Nasdaq
- Market Cap
- MCS 537.6M
- ARVN 456.2M
- IPO Year
- MCS N/A
- ARVN 2018
- Fundamental
- Price
- MCS $16.83
- ARVN $7.70
- Analyst Decision
- MCS Strong Buy
- ARVN Buy
- Analyst Count
- MCS 4
- ARVN 21
- Target Price
- MCS $23.75
- ARVN $20.53
- AVG Volume (30 Days)
- MCS 160.4K
- ARVN 2.1M
- Earning Date
- MCS 07-31-2025
- ARVN 07-29-2025
- Dividend Yield
- MCS 1.65%
- ARVN N/A
- EPS Growth
- MCS N/A
- ARVN N/A
- EPS
- MCS N/A
- ARVN N/A
- Revenue
- MCS $704,626,000.00
- ARVN $426,900,000.00
- Revenue This Year
- MCS $13.05
- ARVN $4.26
- Revenue Next Year
- MCS $4.23
- ARVN N/A
- P/E Ratio
- MCS N/A
- ARVN N/A
- Revenue Growth
- MCS 3.81
- ARVN 498.74
- 52 Week Low
- MCS $10.45
- ARVN $5.90
- 52 Week High
- MCS $23.16
- ARVN $34.11
- Technical
- Relative Strength Index (RSI)
- MCS 43.29
- ARVN 50.16
- Support Level
- MCS $16.49
- ARVN $7.09
- Resistance Level
- MCS $17.14
- ARVN $7.89
- Average True Range (ATR)
- MCS 0.37
- ARVN 0.35
- MACD
- MCS -0.08
- ARVN 0.00
- Stochastic Oscillator
- MCS 24.80
- ARVN 38.14
About MCS Marcus Corporation (The)
Marcus Corp is engaged in two business segments, which are movie theatres and Hotels and Resorts. The movie theatres segment operates multiscreen motion picture theatres in Wisconsin, Illinois, Iowa, Minnesota, Missouri, Nebraska, North Dakota, Ohio and others, a family entertainment center in Wisconsin and a retail center in Missouri; Hotels and Resorts segment owns and operates full-service hotels and resorts in Wisconsin, Illinois, and Nebraska and manages full-service hotels, resorts and other properties in Wisconsin, Minnesota, Texas, Nevada, California, and North Carolina. It generates maximum revenue from the Theatres segment.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.